Inspra is the brand name for the drug eplerenone, a selective potassium-sparing diuretic that blocks mineralocorticoid receptors. It is prescribed to help lower blood pressure and improve heart failure outcomes by reducing sodium retention and fluid overload. The medication works by antagonizing aldosterone at mineralocorticoid receptors in the distal tubules and collecting ducts of the kidney. This antagonism prevents the activation of epithelial sodium channels, leading to increased sodium and water excretion without affecting potassium levels. By decreasing circulating volume and cardiac output, eplerenone reduces the workload on the heart and improves cardiac remodeling in certain conditions. Pharmacodynamically the drug provides selective inhibition that avoids the side effects associated with non-selective mineralocorticoid receptor antagonists. The overall pharmacological action is a reduction in the renin-angiotensin-aldosterone system signaling, which contributes to its antihypertensive and heart-failure benefits.

Inspra is the brand name for the medication eplerenone. It is classified as a selective aldosterone antagonist used primarily to treat high blood pressure. The drug works by blocking the hormone aldosterone from binding to its receptors in the kidneys. This blockade reduces sodium and water retention while promoting potassium retention, which lowers blood volume and pressure. Pharmacologically it is absorbed orally with high bioavailability and is metabolized mainly by the liver into inactive compounds. Its long half-life allows once-daily dosing and a steady reduction of aldosterone-mediated effects. Together these actions make eplerenone useful for managing hypertension and heart failure with preserved ejection fraction.

Inspra may cause mild dizziness in some patients. Headache is another frequently reported symptom. Fatigue can occur during treatment. Elevated potassium levels have been observed in certain individuals. Some users experience coughing or mild respiratory irritation. Low blood pressure may lead to lightheadedness. Rarely patients note kidney-related discomfort. Overall the drug is generally well tolerated.

Inspra may cause changes in blood potassium levels. Some people experience dizziness or lightheadedness. Headache is reported by a portion of users. Fatigue or unusually low energy can occur. A dry cough is occasionally noted. Kidney function tests may show subtle changes in certain cases.